SCHEDULE: FMR LLC Reports 4.1% Stake in Nurix Therapeutics
Beneficial Ownership Report
FMR LLC and Abigail P. Johnson disclose a 4.1% beneficial ownership in Nurix Therapeutics Inc. common stock in an amended Schedule 13G filing.
Summary
- FMR LLC and Abigail P. Johnson have filed an Amendment No. 3 to Schedule 13G, reporting their beneficial ownership in Nurix Therapeutics Inc. common stock.
- As of October 31, 2025, FMR LLC and Abigail P. Johnson beneficially own an aggregate of 4,159,940.33 shares of Nurix Therapeutics Inc. common stock.
- This aggregate amount represents 4.1% of the class of common stock.
- FMR LLC holds sole voting power over 4,156,782.00 shares and sole dispositive power over 4,159,940.33 shares.
- Abigail P. Johnson holds sole dispositive power over 4,159,940.33 shares, with no sole or shared voting power directly.
- The filing indicates that the ownership is 5 percent or less of the class.
- FMR LLC is classified as a parent holding company and operates through various investment adviser and bank subsidiaries, including FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, and Strategic Advisers LLC.
- Abigail P. Johnson is a Director, Chairman, and Chief Executive Officer of FMR LLC, and a predominant owner of FMR LLC's Series B voting common shares.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's operational performance or future prospects. The implied reduction in stake could be seen as slightly negative, but it's a neutral reporting requirement.
Positives
- A significant institutional investor like FMR LLC, along with its CEO Abigail P. Johnson, maintains a substantial beneficial ownership stake in Nurix Therapeutics Inc., which can be viewed as a continued vote of confidence in the company.
Negatives
- The filing indicates that FMR LLC and Abigail P. Johnson's beneficial ownership is now 4.1%, which is below the 5% threshold. As this is an Amendment No. 3, it suggests a reduction from a previous higher stake, potentially signaling decreased conviction or a portfolio rebalancing.
Risks
- The market's perception of a major institutional investor reducing its stake below the 5% threshold could lead to negative sentiment or increased scrutiny of Nurix Therapeutics Inc.'s future prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by a major institutional investor in a publicly traded biotechnology company. It does not provide specific operational or strategic insights into Nurix Therapeutics Inc. or the broader biotechnology industry trends, but rather reflects an investment position.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Governance Disclosure | Members of the Johnson family, including Abigail P. Johnson, are predominant owners of Series B voting common shares of FMR LLC, representing 49% of the voting power. They have a shareholders' voting agreement to vote Series B shares in accordance with the majority vote, potentially forming a controlling group with respect to FMR LLC under the Investment Company Act of 1940. | NA | This describes the internal governance structure of FMR LLC and its control persons, not changes to Nurix Therapeutics Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders may interpret the reduction in FMR LLC's beneficial ownership to below 5% as a potential signal of decreased institutional conviction or a strategic portfolio adjustment, which could influence market perception of Nurix Therapeutics Inc.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2025-10-31 | Date of event which required the filing of this statement. |
| 2025-11-06 | Date of filing and signature for FMR LLC and Abigail P. Johnson. |
Keywords
Nurix Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.